News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,123 Results
Type
Article (14173)
Company Profile (282)
Press Release (251668)
Section
Business (79493)
Career Advice (153)
Deals (13225)
Drug Delivery (35)
Drug Development (50433)
Employer Resources (31)
FDA (5711)
Job Trends (5127)
News (144363)
Policy (10028)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (910)
Accelerated approval (2)
Adcomms (12)
Allergies (49)
Alliances (21632)
ALS (59)
Alzheimer's disease (820)
Antibody-drug conjugate (ADC) (82)
Approvals (5720)
Artificial intelligence (104)
Autoimmune disease (10)
Automation (5)
Bankruptcy (104)
Best Places to Work (4560)
BIOSECURE Act (5)
Biosimilars (38)
Biotechnology (232)
Bladder cancer (42)
Brain cancer (19)
Breast cancer (137)
Cancer (1236)
Cardiovascular disease (100)
Career advice (132)
Career pathing (2)
CAR-T (107)
Cell therapy (302)
Cervical cancer (6)
Clinical research (40808)
Collaboration (491)
Compensation (216)
Complete response letters (13)
COVID-19 (1031)
CRISPR (36)
C-suite (137)
Cystic fibrosis (75)
Data (1287)
Denatured (11)
Depression (28)
Diabetes (122)
Diagnostics (1290)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (76)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (77)
Earnings (29557)
Editorial (17)
Employer branding (4)
Employer resources (29)
Events (48012)
Executive appointments (396)
FDA (6307)
Featured Employer (32)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (457)
Gene editing (86)
Generative AI (9)
Gene therapy (224)
GLP-1 (350)
Government (1074)
Grass and pollen (2)
Guidances (18)
Healthcare (6585)
Huntington's disease (21)
IgA nephropathy (19)
Immunology and inflammation (78)
Indications (18)
Infectious disease (1089)
Inflammatory bowel disease (109)
Inflation Reduction Act (8)
Influenza (17)
Intellectual property (54)
Interviews (17)
IPO (7262)
IRA (11)
Job creations (860)
Job search strategy (127)
Kidney cancer (6)
Labor market (4)
Layoffs (199)
Leadership (2)
Legal (1386)
Liver cancer (30)
Lung cancer (176)
Lymphoma (81)
Machine learning (1)
Management (7)
Manufacturing (113)
MASH (46)
Medical device (2586)
Medtech (2587)
Mergers & acquisitions (6245)
Metabolic disorders (356)
Multiple sclerosis (50)
NASH (13)
Neurodegenerative disease (55)
Neuropsychiatric disorders (23)
Neuroscience (1178)
NextGen: Class of 2025 (2016)
Non-profit (852)
Northern California (1493)
Now hiring (21)
Obesity (183)
Opinion (100)
Ovarian cancer (57)
Pain (40)
Pancreatic cancer (51)
Parkinson's disease (102)
Partnered (6)
Patents (105)
Patient recruitment (64)
Peanut (35)
People (25471)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14409)
Phase II (18984)
Phase III (12002)
Pipeline (635)
Podcasts (45)
Policy (34)
Postmarket research (852)
Preclinical (6036)
Press Release (30)
Prostate cancer (51)
Psychedelics (35)
Radiopharmaceuticals (211)
Rare diseases (267)
Real estate (1414)
Recruiting (12)
Regulatory (8527)
Reports (15)
Research institute (936)
Resumes & cover letters (17)
Rett syndrome (3)
RNA editing (2)
RSV (10)
Schizophrenia (54)
Series A (89)
Series B (57)
Service/supplier (1)
Sickle cell disease (37)
Southern California (1327)
Special edition (11)
Spinal muscular atrophy (116)
Sponsored (11)
Startups (1971)
State (1)
Stomach cancer (4)
Supply chain (18)
The Weekly (33)
United States (11780)
Vaccines (203)
Venture capitalists (28)
Webinars (7)
Weight loss (103)
Women's health (15)
Worklife (2)
Date
Today (75)
Last 7 days (324)
Last 30 days (1654)
Last 365 days (20040)
2025 (4299)
2024 (20552)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16224)
2018 (11738)
2017 (13746)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Alabama (38)
Alaska (2)
Arizona (51)
Arkansas (5)
Asia (17186)
Australia (2913)
California (3415)
Canada (1033)
China (308)
Colorado (129)
Connecticut (141)
Delaware (86)
Europe (36972)
Florida (399)
Georgia (104)
Idaho (16)
Illinois (208)
India (7)
Indiana (84)
Iowa (1)
Japan (66)
Kansas (58)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (438)
Massachusetts (2698)
Michigan (69)
Minnesota (133)
Mississippi (1)
Missouri (22)
Montana (14)
Nebraska (4)
Nevada (15)
New Hampshire (13)
New Jersey (855)
New Mexico (12)
New York (938)
North Carolina (510)
North Dakota (4)
Northern California (1493)
Ohio (107)
Oklahoma (9)
Oregon (21)
Pennsylvania (649)
Puerto Rico (3)
Rhode Island (14)
South America (208)
South Carolina (4)
Southern California (1327)
Tennessee (25)
Texas (386)
Utah (48)
Virginia (66)
Washington D.C. (28)
Washington State (315)
Wisconsin (13)
266,123 Results for "aptevo therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Aptevo to Participate in March 2025 Conferences
March 7, 2025
·
5 min read
Press Releases
Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update
February 17, 2025
·
15 min read
Press Releases
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds
December 13, 2024
·
6 min read
BioForest
Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA
Aptevo Therapeutics Inc. today announced a presentation at The Essential Protein & Antibody Engineering Summit (PEGS) conference in Boston MA.
May 14, 2024
·
8 min read
Press Releases
Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy
March 19, 2025
·
9 min read
Drug Development
Aptevo Therapeutics Provides Pipeline Update
Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced advancements in both clinical programs and one preclinical program.
April 10, 2024
·
12 min read
BioForest
Aptevo Participating in the BIO International Convention 2024
Aptevo Therapeutics Inc. announced that the Company is participating in the BIO International Convention occurring June 3-6, 2024 in San Diego, CA.
June 3, 2024
·
4 min read
Deals
Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules
Aptevo Therapeutics Inc. today announced that it has entered into securities purchase agreements with certain healthcare-focused and institutional investors to purchase (i) 5,339,806 shares of its common stock.
June 28, 2024
·
6 min read
Press Releases
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update
November 7, 2024
·
11 min read
Business
Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update
Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the quarter ended March 31, 2024 and provided a business update.
May 8, 2024
·
13 min read
1 of 26,613
Next
